Epikast provides technology-enabled commercial and clinical services for the biopharmaceutical industry.
Epikast has raised $2.2M in total funding. The most recent round was Series B. The last funding was announced in January 2026.
Epikast's investors include EcoR1 Capital, Kos Biotechnology Partners.
Epikast is headquartered in New York, United States.
Epikast provides technology-enabled commercial and clinical services for the biopharmaceutical industry.
Epikast is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Epikast — Funding & Investors." VCBacked, January 30, 2026, https://www.vcbacked.co/company/epikast. Accessed August 23, 2026.
VCBacked. (2026). Epikast — Funding & Investors. Retrieved August 23, 2026, from https://www.vcbacked.co/company/epikast
{{cite web |title=Epikast — Funding & Investors |url=https://www.vcbacked.co/company/epikast |website=VCBacked |access-date=August 23, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated